Family history of gastric cancer correlates with decreased expression of HINT1 tumor suppressor gene in gastric mucosa of dyspeptic patients

Zuk,Karolina; Peczek,Lukasz; Stec-Michalska,Krystyna; Medrek,Marta; Nawrot,Barbara

doi:10.3892/ol.2011.456

Family history of gastric cancer correlates with decreased expression of HINT1 tumor suppressor gene in gastric mucosa of dyspeptic patients

Authors:
- Karolina Zuk
- Lukasz Peczek
- Krystyna Stec-Michalska
- Marta Medrek
- Barbara Nawrot
View Affiliations

Affiliations: Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Department of Bioorganic Chemistry, Lodz 90-363, Poland, Centre of Molecular and Macromolecular Studies, Polish Academy of Sciences, Department of Bioorganic Chemistry, Lodz 90-363, Poland, Department of Gastroenterology, Medical University of Lodz, Lodz, Poland
Published online on: October 21, 2011 https://doi.org/10.3892/ol.2011.456
Pages: 219-223

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gastric cancer (GC) is the fourth most common cancer and the second most common cause of cancer-associated mortality worldwide. Approximately 10% of gastric cancers are hereditary and a small percentage of these cases (1-3%) have been classified as a single hereditary syndrome (hereditary diffuse gastric cancer). We previously demonstrated that a family history of gastric cancer (FHGC) contributes to a predisposition towards the development of gastric cancer. Our data revealed that for dyspeptic patients whose first‑degree relative(s) succumbed to GC, the levels of the fragile histidine triad pro-apoptotic protein in gastric mucosa were decreased. Another member of the histidine triad protein superfamily is histidine triad nucleotide-binding protein 1 (HINT1), a novel tumor suppressor that plays an inhibitory role in the control of gene transcription. The study comprised 38 ethnically homogeneous patients with dyspeptic symptoms without concomitant chronic diseases (18 controls/20 patients with FHGC). The results showed that the samples from the control patients predominantly exhibited non-atrophic changes (approximately 90%), whereas atrophic changes occurred more frequently in patients with FHGC. Notably, the expression levels of the HINT1 gene were markedly higher in the samples with atrophy taken from the antrum of FHGC patients compared to the non-atrophic samples. Moreover, the levels of HINT1 mRNA in samples obtained from the antrum of patients with FHGC were lower compared to analogous samples from the control individuals. The decreased levels of HINT1 mRNA in the antrum samples of patients with the FHGC indicate that it is a factor predisposing those patients to the development of gastric cancer.

View Figures

View References

1	Oliveira C, Seruca R and Carneiro F: Hereditary gastric cancer. Best Pract Res Clin Gastroenterol. 23:147–157. 2009. View Article : Google Scholar
2	Cisco RM, Ford JM and Norton JA: Hereditary diffuse gastric cancer: implications of genetic testing for screening and prophylactic surgery. Cancer. 113:1850–1856. 2008. View Article : Google Scholar : PubMed/NCBI
3	Fitzgerald RC, Hardwick R, Huntsman D, Carneiro F, Guilford P, Blair V, Chung DC, Norton J, Ragunath K, Van Krieken JH, et al: Hereditary diffuse gastric cancer: updated consensus guidelines for clinical management and directions for future research. International Gastric Cancer Linkage Consortium. J Med Genet. 47:436–444. 2010. View Article : Google Scholar
4	Oliveira C, Bordin MC, Grehan N, Huntsman D, Suriano G, Machado JC, Kiviluoto T, Aaltonen L, Jackson CE and Caldas C: Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. Hum Mutat. 19:510–517. 2002. View Article : Google Scholar : PubMed/NCBI
5	Ishii H, Ozawa K and Furukawa Y: Alteration of the fragile histidine triad gene early in carcinogenesis: an update. J Exp Ther Oncol. 3:291–296. 2003. View Article : Google Scholar : PubMed/NCBI
6	Stec-Michalska K, Antoszczyk S, Klupinska G and Nawrot B: Loss of FHIT expression in the gastric mucosa of patients with family history of gastric cancer and Helicobacter pylori infection. World J Gastroenterol. 11:17–21. 2005. View Article : Google Scholar : PubMed/NCBI
7	Stec-Michalska K, Peczek L, Michalski B, Wisniewska-Jarosinska M, Krakowiak A and Nawrot B: Helicobacter pylori infection and family history of gastric cancer decrease expression of FHIT tumor suppressor gene in gastric mucosa of dyspeptic patients. Helicobacter. 14:126–134. 2009. View Article : Google Scholar
8	Baffa R, Veronese ML, Santoro R, Mandes B, Palazzo JP, Rugge M, Santoro E, Croce CM and Huebner K: Loss of FHIT expression in gastric carcinoma. Cancer Res. 58:4708–4714. 1998.PubMed/NCBI
9	Lee SH, Kim WH, Kim HK, Woo KM, Nam HS, Kim HS, Kim JG and Cho MH: Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas. Biochem Biophys Res Commun. 284:850–855. 2001. View Article : Google Scholar : PubMed/NCBI
10	Weiske J and Huber O: The histidine triad protein HINT1 triggers apoptosis independent of its enzymatic activity. J Biol Chem. 281:27356–27366. 2006. View Article : Google Scholar : PubMed/NCBI
11	Su T, Suzui M, Wang L, Lin CS, Xing WQ and Weinstein IB: Deletion of histidine triad nucleotide-binding protein 1/PKC-interacting protein in mice enhances cell growth and carcinogenesis. Proc Natl Acad Sci USA. 100:7824–7829. 2003. View Article : Google Scholar : PubMed/NCBI
12	Wang L, Zhang Y, Li H, Xu Z, Santella RM and Weinstein IB: HINT1 inhibits growth and activator protein-1 activity in human colon cancer cells. Cancer Res. 67:4700–4708. 2007. View Article : Google Scholar : PubMed/NCBI
13	Li H, Zhang Y, Su T, Santella RM and Weinstein IB: HINT1 is a haplo-insufficient tumor suppressor in mice. Oncogene. 25:713–721. 2006. View Article : Google Scholar : PubMed/NCBI
14	Zhang YJ, Li H, Wu HC, Shen J, Wang L, Yu MW, Lee PH, Weinstein IB and Santella RM: Silencing of HINT1, a novel tumor suppressor gene, by promoter hypermethylation in hepatocellular carcinoma. Cancer Lett. 275:277–284. 2009. View Article : Google Scholar : PubMed/NCBI
15	Dixon MF, Genta RM, Yardley JH and Correa P: Classification and grading of gastritis. The updated Sydney System International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 20:1161–1181. 1996.PubMed/NCBI
16	Korsisaari N and Makela TP: Interactions of Cdk7 and Kin28 with Hint/PKCI-1 and Hnt1 histidine triad proteins. J Biol Chem. 275:34837–34840. 2000. View Article : Google Scholar : PubMed/NCBI
17	Weiske J and Huber O: The histidine triad protein HINT1 interacts with Pontin and Reptin and inhibits TCF-beta-catenin- mediated transcription. J Cell Sci. 118:3117–3129. 2005. View Article : Google Scholar : PubMed/NCBI
18	Wang L, Li H, Zhang Y, Santella RM and Weinstein IB: HINT1 inhibits beta-catenin/TCF4, USF2 and NFkappaB activity in human hepatoma cells. Int J Cancer. 124:1526–1534. 2009. View Article : Google Scholar : PubMed/NCBI
19	Huang H, Wei X, Su X, Qiao F, Xu Z, Gu D, Fan H and Chen J: Clinical significance of expression of Hint1 and potential epigenetic mechanism in gastric cancer. Int J Oncol. 38:1557–1564. 2011.
20	Guranowski A, Wojdyła AM, Pietrowska-Borek M, Bieganowski P, Khurs EN, Cliff MJ, Blackburn GM, Błaziak D and Stec WJ: Fhit proteins can also recognize substrates other than dinucleoside polyphosphates. FEBS Lett. 582:3152–3158. 2008. View Article : Google Scholar
21	Stec-Michalska K: Clinical aspects of changes of the level of expression of selected proapoptotic genes in the gastric mucosa of patients with family history of gastric cancer (habilitation dissertation). Medical University of Lodz; Poland: 2010